Figure 3
![Figure 3. Outcome according to presence of antigenic mismatch. (A) CI of ceGVHD including cases occurring post-DLI. (B) CI of TRM (28% [21%-38%] vs 23% [13%-41%] at 1 year). (C) Kaplan-Meier curves of OS.](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/115/25/10.1182_blood-2010-01-265413/4/zh89991054070003.jpeg?Expires=1724259257&Signature=BOAJoyWfaXJtYI-CZoQqVXEDcWXckxcKnV~BVpa0JJ0cCbv4E~HHejsJyuQCV7UxYYsegpfnET5nYGNYPzV~YS9LykZw2oniqyzRrBLB-UhyQcgPSvs58Uinwv1iBxwCkGn8p7J6dqVqxWil3YuoKfE0p3d5EFa2X6sOvM02t2V-FEq1jjMts~rVOPRzaxG0heYr~rHrsc0SZfRRubmcae8yay7G21iRyBgbAGxVBNsuayUVxD~PtLJhiEcTdcz~UhwSl052v~S5unSSgFetjfMn5HohhIgjpw6ean6Y2RMeh6lscYNttcIVpj-yDk-d6oMYrefAI9Hqh2zERguuMA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Outcome according to presence of antigenic mismatch. (A) CI of ceGVHD including cases occurring post-DLI. (B) CI of TRM (28% [21%-38%] vs 23% [13%-41%] at 1 year). (C) Kaplan-Meier curves of OS.
Outcome according to presence of antigenic mismatch. (A) CI of ceGVHD including cases occurring post-DLI. (B) CI of TRM (28% [21%-38%] vs 23% [13%-41%] at 1 year). (C) Kaplan-Meier curves of OS.
